
BRD0418
CAS No. 1565827-99-7
BRD0418( —— )
Catalog No. M34528 CAS No. 1565827-99-7
BRD0418 acts as an upregulator of TRIB1 expression by leading to reprogramming of hepatic lipoprotein metabolism from adipogenesis to clearance it.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 296 | Get Quote |
![]() ![]() |
5MG | 425 | Get Quote |
![]() ![]() |
10MG | 626 | Get Quote |
![]() ![]() |
25MG | 908 | Get Quote |
![]() ![]() |
50MG | 1270 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameBRD0418
-
NoteResearch use only, not for human use.
-
Brief DescriptionBRD0418 acts as an upregulator of TRIB1 expression by leading to reprogramming of hepatic lipoprotein metabolism from adipogenesis to clearance it.
-
DescriptionBRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1565827-99-7
-
Formula Weight488.57
-
Molecular FormulaC29H32N2O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(O)[C@H]1[C@]2([C@](C=3C(O2)=CC=C(N(C)C)C3)(C[C@@H](CC(NCC4=CC=C(OC5=CC=CC=C5)C=C4)=O)O1)[H])[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nagiec MM, et al. Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression. PLoS One. 2015 Mar 26;10(3):e0120295.?
molnova catalog



related products
-
RS5517
RS5517 is a novel PDZ1 structural domain ligand for the study of colorectal cancer.
-
9-Methyl-9H-beta-car...
The herbs of Rauvolfia verticillata.
-
Azelaprag
Azelaprag (AMG 986) is an effective small-molecule apelin receptor agonist. Azelaprag can be used to treat neurological diseases and cardiovascular diseases.